Alvotech maintains a Hold rating after missing H1 2026 earnings expectations and facing regulatory challenges, including FDA Complete Response Letters (CRLs) for its biosimilars AVT05 and AVT06 due to manufacturing issues now resolved. The company has resubmitted Biologics License Applications (BLAs) and aims for multiple approvals by Q4 2026. AVT06, a biosimilar to EYLEA, has secured global commercialization rights post-November 2026, with patent disputes settled, presenting a significant market opportunity. However, Alvotech's cash runway is limited to 12 months, and further financing may be needed, potentially causing dilution as it supports commercialization efforts.
Youdao reported strong Q2 2026 results, with earnings per share of $0.11 beating estimates of $0.02 and revenue rising 3.5% year-over-year to $216.20 million. The company achieved its eighth consecutive quarter of operating profitability, recording a...
ScanSource reported strong Q4 results with non-GAAP earnings of $1.46 per share, surpassing estimates by over 31%, and net sales rising 17.3% to $953.11 million driven by hardware demand and growth in North America. The company announced a $220.5 mil...
Scotiabank raised its price target for Simon Property Group to $222 from $220 while maintaining a neutral Sector Perform rating. The real estate trust reported a 19.5% revenue increase to $1.79 billion in Q2 2026, with stable 96% occupancy at its U.S...
UiPath CEO Daniel Dines has sold 1.4 million shares of the company, raising $22.5 million. This move may indicate a personal liquidity event or portfolio rebalancing by the CEO. Investors might watch for any impact on the stock price or future inside...
NetEase reported Q2 2026 earnings with revenue of approximately $4.40 billion, surpassing analyst expectations of $4.33 billion, driven by a 10% year-over-year increase in its games and value-added services segment. However, earnings per share fell s...
